Penile enlargement without surgery with the Andropenis Device
Scientific Research presented in the
1st Virtual Sexology and Hispanoamerican Sexual Education
Congress (February -2001); Dr. Eduardo A. Gomez de Diego
„ 1998 Andrology Services ,Andromedical Clinic, Madrid (Spain)
1. Introduction:
When the human tissues are submitted to a
force of traction, they react by increasing in size.
The principle of traction is applied in modern medicine,
for the generation of new tissue to cover burn wounds or
areas of hair loss ( placing a tissular expander underneath
the normal skin ) or for the lengthening of bones.
In other cultures this principle is applied to lengthen
different parts of the body like the Giraffe Women of the
Paduang tribe in Birmania ; or the lengthening of the lips
in certain African tribes of Africa that use wood to create
traction; and in India where they hang stones on the penis
of men as a form of penitence with the resulting enlargement
of the organ.
Based on this principle of external traction the Andropenis®
was designed . It is able to exhort a gradual traction force
of 600 to 1500 grams.
The device consists of a plastic ring, where the penis is
introduced and from where 2 dynamic metalic rods that originate
the traction. In the superior part there is a plastic support
where a silicone band holds the glans in place.
Based on our clinical experience
the traction device yields the following results:
- An increase in the length of the penis in erection
and flaccidity.
- An increase in the perimeter of the penis in erection
and flaccidity.
- This results will be analyzed statistically to be
verified and quantified
2. Materials and Methods
Number of patients: 37 patients, ages
between 22 and 60 years of age. These men proceed from different
cities in Spain.
Selection of patients: patients included were
healthy men with normal erection capabilities and without
penile surgeries. Patients with penile or other diseases
where excluded from the studies.
Traction device:
The Andropenis®, Spanish penile traction
device.
Traction Force: 600 gr during 1st month, 900
gr during 2nd month, 1100 gr durante 3th and 4th mes, and
1200 gr during 5th y 6th month.
Usage period: 10 hours a day, during every
day of the month for a period of 3-6 months.
3. Results
3.1.- INCREASE IN LENGTH IN ERECTION:
The average increase in the length of the
penis in erection by month is of 0.4726 cm. The standard
deviation is of 0.1329 cm. The confidential interval of
95% is of [0.4283 ; 0.5169] which indicates a minimal gain
in the population of 0.4283 cm/month.
Regression line is:
DL erec = - 0.327 + 0.562 x t
This calculation will allow us to estimate the increase
in length of the penis in erection, based on the months
of use of the device. There is a 57.7% variance in the increment
in longitude, which is explained by the variance in the
duration of treatment ( R2= 0.577 ). The other 42.3% is
due to other differences innate to each individual and not
relative to the duration of the treatment
3.2.- INCREMENT IN LENGTH IN THE
FLACCID STATE
The increment in length in the flaccid state
is relative to the time of usage of the device. Such an
increment is linear as shown in the graph. The longer the
device is used, the greater the increase in length. The
coefficient of the linear correlation between the time of
usage and the increment in longitude in the flaccid state
is of 0.725 ( p=0.000 ).
The average monthly increment in longitude
of the penis in the flaccid state is 0.4834 cm and the typical
deviation is 0.1983 cm. The confidence interval of 95% is
of [0.4173 ; 0.5495] and indicates a minimum increase in
the population of 0.4173 cm/month.
Regression line is:
DL flac = - 1.300 + 0.840 x t
This calculation allows us to estimate the increment in
longitude in the flaccid state based on the months in which
the device is used. There is a 52.5% variance in the increment
in longitud which is explained by the variance of the duration
of treatment ( R2= 0.525 ). The other 47.5% is due to other
differences innates to the individual and not relative to
the duration of the treatment.
3.3.- VARIABILITY:
The variability in the increment in longitude
in erection is different from that of flaccidity, being
the difference in variance significant ( p= 0.003 ) which
indicates a greater dispersion of the increases in length
during flaccidity than in erection.
3.4.- THE INCREMENT IN LONGITUDE
DOES NOT DEPEND ON THE AGE:
A very interesting result was that the increment
in longitude does not depend on the age of the patient,
since the coefficient of the linear correlation is not significant
( r=0.008, p=0.961). In other words, the age of the patient
does not effect the increment in longitude.
-
-
-
-
3.7.- LONGITUDE INCREASE IN ERECTION
STATE DEPENDING ON USE:
Dividing the population studied in four sub
groups depending on the usage time of the
Andropenis. we obtain the following
results.
Three months usage:
The median longitude increment in erection state was 1.4118,
obtaining a median growth of 10.5580% over the initial longitude.
The confidence interval of 95% of the studied population
was ( 1.1522; 1.6713) which shows a median minimal growth
of 1.1522 cm in three months.
Four months usage:
The median longitude increment in erection state was 1.8462,
obtaining a median growth of 14.1113% over the initial longitude.
The confidence interval of 95% of the studied population
was(1.5809; 2.1114) which shows a median minimal growth
of 1.5809 cm in four months.
Five months usage:
The median longitude increment in erection state was 2.2750,
obtaining a median growth of 16.6303% over the initial longitude.
The confidence interval of 95% of the population studied
was (1.7656; 2.7844) which shows a median minimal growth
of 1.7656 cm in four months.
Six months usage:
The median longitude increment in erection state was 3.3333,
obtaining a median growth of 27.5% over the initial longitude.
The confidential interval of 95% of the population studied
was (2.8162; 3.8504) which shows a median minimal growth
of 2.8162 cm in six months.
The samples corresponding to five and six months are very
small which makes small intervals and less reliable.
3.8.- DISTRIBUTION:
Although the variables considered in the population
are not normal, the median samples, have normal distribution
since the amount of the sample is greater than 20.
3.9.- ABBREVIATIONS:
Inc-Long-Erec
|
Longitude
increment in erection state |
DL erec
|
Change
in Longitude increment in erection state |
I.L.ERT
|
Longitude
increment in erection as a function of the time
variable |
I.L.FLAC
|
Longitude
increment in flaccid state |
DL flac
|
Change
in Longitude increment in flaccid state |
I.L.FLT
|
Longitude
increment in flaccid state in function of time |
Inc-Long-Erec
|
Longitude
increment in erection state |
% I Long-Erec
|
Longitude
increment percentage in erection state. |
4. Conclusions
The use of the Spanish traction device (Andropenis)
will increase the length of the penis, both in the erectile
and flaccid state.
The increase in length, both in and flaccidity, is directly
proportional to the time of use.
The increase in length both in erection and flaccidity,
does not depend on the natural size of the patient.
The average growth in length of the penis in cm/month in
95% of the patients was between 0.4283 and 0.5163 in erection,
and between 0.4173 and 0.5495 in flaccidity.
The increments of change in length of the penis in erection
are more uniform than those in flaccidity which tend to
be more disparate .
The increment of change in the length of the penis in erection
is not relative to the age of the patient.
The use of the penile traction device will increase the
perimeter of the penis, both in erection and flaccidity.
The average growth in perimeter in cm/month in 95% of the
patients was between 0.6111 and 1.0200 in erection, and
between 0.6386 and 1.0425 in flaccidity. Treatment was 3-6
months duration.
5. Anex
PATIENT RESULTS (Using the
Andropenis):
Nombre
|
Edad |
Inicio |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Meses |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
LAA |
60 |
15.1.98 |
12.0 |
8.0 |
12.0 |
10.0 |
3.0 |
13.5 |
9.0 |
13.5 |
10.5 |
EAG |
37 |
30.1.98 |
14.5 |
8.0 |
12.0 |
8.5 |
4.0 |
16.5 |
9.5 |
13.0 |
10.5 |
VA |
27 |
26.11.97 |
16.3 |
10.4 |
13.9 |
10.1 |
3.0 |
17.8 |
12.5 |
14.5 |
11.5 |
EAA |
46 |
15.3.98 |
14.5 |
10.5 |
12.0 |
10.0 |
6.0 |
17.6 |
15.7 |
13.2 |
11.2 |
JBV |
25 |
27.3.98 |
15.0 |
8.0 |
13.0 |
9.0 |
3.0 |
16.6 |
9.5 |
13.3 |
10.5 |
ABB |
39 |
29.6.98 |
14.0 |
11.0 |
13.0 |
11.0 |
3.0 |
15.5 |
12.5 |
14.0 |
12.0 |
CBG |
37 |
19.1.98 |
12.5 |
6.0 |
12.0 |
9.0 |
4.0 |
14.0 |
8.8 |
12.5 |
9.4 |
JBL |
25 |
7.5.98 |
13.7 |
9.0 |
11.5 |
10.0 |
4.0 |
16.3 |
11.5 |
13.5 |
12.0 |
JCB |
27 |
19.11.97 |
13.0 |
8.0 |
14.5 |
12.0 |
6.0 |
16.4 |
11.1 |
14.2 |
12.2 |
JJCA |
33 |
1.6.98 |
10.5 |
4.9 |
11.0 |
9.5 |
3.0 |
12.0 |
5.5 |
11.5 |
9.5 |
JCA |
32 |
4.2.98 |
14.0 |
10.0 |
10.0 |
9.0 |
4.0 |
15.9 |
12.0 |
12.2 |
10.5 |
ODV |
25 |
4.3.98 |
16.5 |
9.5 |
13.0 |
9.7 |
3.0 |
18.0 |
11.0 |
13.3 |
10.0 |
PDS |
22 |
10.6.98 |
14.4 |
8.3 |
11.0 |
7.8 |
3.0 |
15.8 |
9.0 |
11.6 |
8.3 |
AGM |
41 |
26.11.98 |
13.0 |
9.0 |
11.0 |
10.0 |
4.0 |
15.0 |
9.5 |
11.0 |
10.0 |
MGF |
32 |
29.9.97 |
12.5 |
5.5 |
12.5 |
10.0 |
4.0 |
14.5 |
8.0 |
13.0 |
10.0 |
AHM |
44 |
5.3.98 |
11.5 |
8.0 |
13.0 |
12.0 |
3.0 |
13.0 |
9.5 |
14.0 |
12.0 |
AAMP |
37 |
12.3.98 |
12.7 |
7.0 |
10.5 |
7.5 |
3.0 |
14.0 |
9.0 |
11.0 |
9.0 |
JLMO |
34 |
30.1.98 |
14.8 |
11.0 |
11.0 |
9.3 |
4.0 |
15.8 |
11.0 |
12.7 |
9.3 |
JAMV |
41 |
28.7.97 |
17.0 |
10.0 |
14.0 |
12.5 |
5.0 |
19.6 |
12.3 |
15.0 |
13.5 |
FOR |
8% |
9.11.97 |
12.5 |
7.0 |
10.0 |
9.0 |
5.0 |
14.5 |
11.0 |
11.0 |
10.5 |
ROM |
28 |
12.11.97 |
16.0 |
8.5 |
13.0 |
9.0 |
5.0 |
18.0 |
12.5 |
13.5 |
10.5 |
JPC |
33 |
16.1.98 |
13.7 |
7.2 |
12.3 |
10.1 |
3.0 |
16.7 |
8.7 |
13.1 |
10.9 |
JAPG |
29 |
4.11.97 |
10.0 |
8.0 |
12.0 |
10.0 |
6.0 |
13.5 |
11.5 |
13.0 |
11.0 |
FPR |
8% |
20.3.98 |
10.5 |
7.0 |
12.0 |
10.0 |
3.0 |
11.3 |
7.3 |
12.7 |
10.0 |
JPF |
42 |
23.3.98 |
13.0 |
7.0 |
13.0 |
10.0 |
3.0 |
14.5 |
8.5 |
13.0 |
10.5 |
AJRF |
26 |
28.11.97 |
14.0 |
9.0 |
13.0 |
9.0 |
4.0 |
16.0 |
10.7 |
13.0 |
10.0 |
ARR |
58 |
7.10.97 |
11.0 |
7.0 |
11.0 |
9.0 |
3.0 |
12.0 |
8.0 |
12.0 |
10.0 |
RRG |
25 |
25.11.97 |
14.5 |
11.0 |
11.0 |
10.0 |
3.0 |
15.0 |
12.4 |
11.7 |
10.8 |
CSM |
35 |
24.2.98 |
15.0 |
9.0 |
11.0 |
9.0 |
3.0 |
16.5 |
11.0 |
12.0 |
10.0 |
ASE |
35 |
20.3.98 |
12.5 |
7.5 |
11.5 |
9.0 |
4.0 |
14.5 |
9.5 |
12.5 |
10.5 |
ASPA |
42 |
7.11.97 |
14.0 |
7.5 |
12.0 |
9.0 |
4.0 |
16.0 |
9.5 |
13.0 |
10.5 |
SSF |
27 |
15.8.97 |
14.5 |
7.0 |
14.5 |
8.0 |
3.0 |
15.9 |
8.0 |
15.0 |
8.7 |
ISB |
22 |
23.9.97 |
11.5 |
7.5 |
11.0 |
9.5 |
4.0 |
13.5 |
10.2 |
11.3 |
10.3 |
FT |
53 |
19.11.97 |
14.5 |
10.0 |
13.0 |
10.0 |
3.0 |
16.0 |
11.5 |
13.5 |
10.5 |
EVC |
24 |
29.12.97 |
11.0 |
7.0 |
11.5 |
9.0 |
5.0 |
13.5 |
9.0 |
12.5 |
10.5 |
PV |
33 |
8.10.97 |
12.0 |
8.5 |
15.5 |
13.0 |
4.0 |
13.0 |
9.5 |
16.0 |
13.0 |
JSVS |
32 |
24.1.98 |
12.0 |
6.0 |
10.5 |
9.0 |
4.0 |
14.0 |
8.5 |
12.5 |
9.5 |
L-Erec1 = Length in Erection initial
L-Flac1 = Length in Flaccidity inicial
P-Erec1 = Perimeter in Erection initial
P-Flac1 = Perimeter in Flaccidity inicial
L-Erec2 = Length in Erection final
L-Flac2 = Length in Flaccidity final
P-Erec2 = Perimeter in Erection final
P-Flac2 = Perimeter in Flaccidity final
|